论文部分内容阅读
采用流式细胞仪测定红细胞CD35 (RBC CD35 ) ,用免疫酶联法测定红细胞趋化因子受体 (ECKR) ,研究肿瘤患者红细胞CD35与趋化因子受体的变化规律。结果显示 ,2 5例肿瘤患者红细胞CD35数量 (41 0 2± 14 86 )、ECKR活性 (46 0 5± 13 33)明显低于 2 9例正常人的相应指标水平 (5 3 39± 39 2 2和 5 3 5 8± 10 2 6 ,P <0 0 5 )。肿瘤患者血清细胞介素 8(sIL 8)含量 (3 37± 2 5 9)高于正常人(2 92± 1 0 7) ,鼻咽癌患者RBC CD35数量 (2 6 0 6± 3 0 0 )明显低于其他肿瘤患者 (38 90～ 5 2 4 7,P <0 0 5 )。提示肿瘤患者红细胞天然免疫分子与sIL 8之间存在一定的相关性 ,红细胞天然免疫分子变化的分析为免疫反应的调控规律及临床提供了有用的信息
The erythrocyte CD35 (RBC CD35) was determined by flow cytometry. The erythrocyte chemotactic factor receptor (ECKR) was determined by enzyme-linked immunosorbent assay (ELISA), and the changes of erythrocyte CD35 and chemokine receptor in tumor patients were studied. The results showed that the number of erythrocyte CD35 (41 0 2 ± 14 86) and ECKR activity (46 0 5 ± 13 33) in 25 cancer patients were significantly lower than that of 29 healthy individuals (5393 ± 39 2 2 And 5 3 5 8 ± 10 2 6, P <0 0 5). The serum level of sIL 8 in cancer patients (377 ± 259) was higher than that in healthy controls (2952 ± 107) and the number of RBC CD35 in patients with nasopharyngeal cancer was (26 06 ± 30) Significantly lower than other tumor patients (38 90 ~ 5247, P <0 05). Suggesting that there is a certain correlation between innate immune molecules of erythrocytes and sIL 8 in tumor patients. The analysis of molecular changes of innate immunity of erythrocytes provides useful information for regulating regulation and clinical of immune response